PREM SHRESTHA: Open Payments
NPI 1780202077 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$754 in 42 payments from 12 companies in 2025. Trend: 2023 $903 · 2024 $2,145 · 2025 $754
Food & beverage: $675Education: $79
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $281 |
| Aimmune Therapeutics, Inc. | 17 | $164 |
| Madrigal Pharmaceuticals | 3 | $67 |
| Gilead Sciences, Inc. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Celltrion USA Inc. | 1 | $23 |
| RedHill Biopharma Inc. | 1 | $23 |
| Novo Nordisk Inc | 1 | $23 |
Products named: TREMFYA, ZENPEP, REZDIFFRA, DUPIXENT, IQIRVO, XIFAXAN, VEGZELMA, Talicia.
Industry payments across TX — which companies pay providers there.
